Viking Therapeutics Releases Third Quarter Financial Results
Conference call scheduled for later in the day
Trending Developments Include:
- Progress on Phase 3 VANQUISH Trials for VK2735 in Obesity
- VK2735 Phase 1 Maintenance Dosing Study in Progress
- Introduction of Additional Phase 2a VENTURE Study Data at Upcoming Conferences
- Robust Cash Position of $715 Million at Quarter-End
Viking Therapeutics, Inc. (NASDAQ: VKTX), a biopharmaceutical company focused on innovative treatments for metabolic and endocrine disorders, recently announced its financial results for the third quarter and provided insight into its ongoing clinical programs. The announcement reflects their efforts in developing novel therapies and highlights the performance of their lead drug candidate VK2735.
Major Highlights for the Quarter Ended September 30, 2025:
Brian Lian, Ph.D., CEO of Viking, remarked, "We have made significant advancements across our active programs throughout 2025. New data emerging this quarter further consolidates VK2735’s potential as a leading obesity treatment option. Notably, the Phase 2 VENTURE-Oral Dosing study yielded promising results, enabling participants to achieve weight loss of up to 12.2% from baseline in just 13 weeks. We are excited about the implications of these findings for treatment options available to patients. "
The VENTURE-Oral Dosing study showed that participants maintained significant weight loss with a once-daily oral dose of VK2735, with a cohort demonstrating a promising safety profile throughout the study. These results provide valuable information for future dosing strategies and reinforce Viking’s commitment to developing comprehensive obesity treatments.
Pipeline Progress and Other Corporate Updates
- VANQUISH Trials for VK2735 on Schedule - This study is evaluating the efficacy and safety of VK2735, a dual agonist targeting the GLP-1 and GIP receptors, designed for treating obesity and related conditions. This phase marks a critical step towards the commercialization of this innovative therapy.
- VENTURE Oral Dosing Results - The study successfully met its primary and secondary endpoints, showing substantial weight reductions, encouraging safety, and tolerability data, setting it apart from existing obesity treatments.
- VK2735 Maintenance Dosing Study on Track - A Phase 1 study is currently underway focusing on various maintenance dosing regimens to help sustain the weight loss achieved, further supporting personalized patient treatment plans.
- Exploration of DACRA Program - Viking continues developing its dual Amylin and Calcitonin receptor agonist (DACRA) program, which holds potential therapeutic benefits for obesity, planning to submit an IND application in early 2026.
- Upcoming Presentations - Expected presentations at significant scientific conferences will highlight VK2735's effectiveness in weight management and diabetes management.
Financial Overview
For the third quarter, Viking reported a net loss of $90.8 million, equating to $0.81 per share. Research and development expenses significantly increased, driven by clinical developments, yet Viking's cash reserves bolster its capabilities for ongoing and future studies.
Comparatively, for the nine months ending in September 2025, Viking’s total net loss reached $202 million, reflecting investments in clinical trials and the overall expansion of its research pipeline.
As of September 30, 2025, the company retained cash, cash equivalents, and short-term investments totaling $715 million, down from $903 million as of year-end 2024, emphasizing a continuing commitment to advancing its clinical pipelines.
Conclusion and Future Directions
Viking Therapeutics shows strong momentum in its clinical programs aimed at treating obesity, continuing to advance its innovative VK2735 program while managing finances effectively. With a solid cash position and promising clinical data, the company is strategically positioned for future growth and development.
Frequently Asked Questions
What are the recent financial results for Viking Therapeutics?
Viking reported a net loss of $90.8 million for the third quarter, primarily due to increased R&D expenses.
What developments have been made in the VK2735 trials?
VK2735's Phase 2 VENTURE study achieved significant weight loss results, reinforcing its potential as a leading obesity treatment.
When is the expected completion of the VANQUISH Trial enrollment?
The company anticipates completing enrollment for the VANQUISH-1 trial by the end of 2025, followed by VANQUISH-2 in early 2026.
How is Viking addressing long-term weight maintenance?
The company initiated a Phase 1 study evaluating various maintenance dosing regimens for VK2735, focusing on sustaining weight loss achieved during initial therapies.
What is Viking's cash position as of the last report?
As of September 30, 2025, Viking held $715 million in cash, cash equivalents, and short-term investments, supporting ongoing projects.
